Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development

Egis' medicines won the Innovation Grand Prize
Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize. More

The first and only fixed-dose combination of atorvastatin and esetimibe in Russia

Egis launches in Russia a product with fixed-doses of atorvastatin and ezetimibe in one capsule for the treatment of hypercholesterolemia [1]. Fixed-dose combination (FDC) developed by Egis will increase adherence in patients who take atorvastatin and ezetimibe separately, and a single dose per day should significantly simplify the drug therapy regimen. More

Egis has launched a new ezetimibe of European quality to reduce of cardiovascular disease risks

Egis has launched to the Russian market a new ezetimibe of European quality that helps to achieve the target level of low-density lipoprotein cholesterol in cases where the statin therapy is not enough. The drug is produced in Hungary (EU) in accordance with Good Manufacturing Practices (GMP). At the same time, the new product is more affordable compared to the original ezetimibe [6], which ensures its high attractiveness for Russian doctors and their patients. The product has already been registered in Russia and sold in Russian pharmacies from October 2021. More

Egis Inaugurates Two New Plants in Körmend

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

More

Egis launches the first in Russia drug combination treatment for lowering cholesterol levels¹

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.

More
Other channels
Egis World
Egis' products are sold to 100 countries.
Our People
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
Health
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products
Corporate Social Responsibility
Healthcare and sharing knowledge are in the heart of our CSR activities
Events
Our highlighted past and future events you shouldn't miss
Quick news

New features of the Neuroscanner mobile app will help doctors diagnose dementia and depression

Feb. 21.
More

"Science against allergies": new advertising campaign of Suprastinex®

Apr. 16.
More

Egis reminds what protection you need in case of acute and sudden allergies

Feb. 09.
More

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox